Results 41 to 50 of about 10,598 (216)

NTRK Gene Fusion Detection in Atypical Spitz Tumors [PDF]

International Journal of Molecular Sciences, 2021
Atypical Spitz tumors (AST) deviate from stereotypical Spitz nevi for one or more atypical features and are now regarded as an intermediate category of melanocytic tumors with uncertain malignant potential. Activating NTRK1/NTRK3 fusions elicit oncogenic events in Spitz lesions and are targetable with kinase inhibitors.
Rocco Cappellesso, Filippo Nozzoli, Federica Zito Marino, Sara Simi, Francesca Castiglione, Vincenzo De Giorgi, Carlo Cota, Rebecca Senetta, Giosuè Scognamiglio, Anna Maria Anniciello, Anna Maria Cesinaro, Mario Mandalà, Andrea Gianatti, Maria Gabriella Valente, Barbara Valeri, Angela Rita Sementa, Costantino Ricci, Barbara Corti, Giandomenico Roviello, Angelo Paolo Dei Tos, Renato Franco, Daniela Massi   +21 more
openaire   +3 more sources

Identificación de genes de fusión NTRK. Experiencia en México

Gaceta Mexicana de Oncología, 2023
Objetivo: Evaluar la prevalencia de fusiones TRK en pacientes con cáncer en México. Material y métodos: En un estudio de tipo canasta, se determinó la presencia de genes de fusión NTRK, mediante inmunohistoquímica y secuenciación de nueva generación, en ...
Leticia Bornstein-Quevedo, Claudia Bautista-Wong, Zaira Mojica-González, Mario Gámez-Rosales, Katia Hop-García   +4 more
doaj   +1 more source

NTRK-fusion detection in thyroid and salivary gland cancer offers a targeted therapy with NTRK-inhibitor

GSC Biological and Pharmaceutical Sciences, 2023
NTRK-fusion in cancer is rare but it offers targeted therapy with NTRK-inhibitor. NTRK fusion is not a point mutation. NTRK fusion is an oncogenic driver, NTRK mutation is not an oncogenic driver. Patients with NTRK point mutation do not respond to NTRK-targeted therapy. NTRK fusion was detected in secretory carcinoma.
Hana Evangelin Prayogo, Willy Sandhika
openaire   +1 more source

173P Entrectinib in NTRK fusion-positive (NTRK-fp) breast cancer: Updated data from STARTRK-2

, 2022
International audienceBackgroundFusions in the neurotrophic tyrosine receptor kinase (NTRK) genes act as oncogenic drivers in many solid tumours, including secretory and non-secretory breast cancers. In the phase 2 STARTRK-2 clinical trial (NCT02568267),
C.M. Blakely, Blakely, C.M., M. Barve, D. Klingbiel, M.J. Krzakowski, Delord, J-P., J. Lu, Hu, X., K. Yonemori, X. Hu, D.T. Chen, S.N. Waqar, Waqar, S.N., J-P. Delord, S. Heinzmann, Heinzmann, S., Chen, D.T., Barve, M., Le Tourneau, C., C.H. Chung, Yonemori, K., Lu, J., Klingbiel, D., C. Le Tourneau, Krzakowski, M.J., Chung, C.H.   +25 more
core   +1 more source

Systematic population-based identification of NTRK and RET fusion-positive thyroid cancers

European Thyroid Journal, 2023
Objective: The aim of the study was to identify patients with NTRK fusion-positive or RET fusion/mutation-positive thyroid cancers, who could benefit from neurotrophic tyrosine kinase receptor (NTRK) or receptor tyrosine kinase (RET) inhibitors ...
Markus Eszlinger, Paul Stewardson, John B McIntyre, Adrian Box, Moosa Khalil, Martin Hyrcza, Konstantin Koro, Dean Ruether, Jiahui Wu, Ralf Paschke   +9 more
doaj   +1 more source

Revisiting NTRKs as an emerging oncogene in hematological malignancies [PDF]

Leukemia, 2019
AbstractNTRK fusions are dominant oncogenic drivers found in rare solid tumors. These fusions have also been identified in more common cancers, such as lung and colorectal carcinomas, albeit at low frequencies. Patients harboring these fusions demonstrate significant clinical response to inhibitors such as entrectinib and larotrectinib.
Joshi, Sunil K., Davare, Monika A., Druker, Brian J., Tognon, Cristina E.   +3 more
openaire   +2 more sources

Efficacy of immune checkpoint inhibitors in non-small cell lung cancer with NTRK family mutations

BMC Pulmonary Medicine, 2023
Background The efficacy of immune checkpoint inhibitors (ICIs) in non-small cell lung cancer (NSCLC) patients harboring neurotrophin receptor kinase (NTRK) family mutations remains obscure. Methods The Zehir cohort from cBioPortal was used to analyze the
Xiaoling Shang, Wengang Zhang, Wenfei Han, Handai Xia, Ni Liu, Xiuwen Wang, Yanguo Liu   +6 more
doaj   +1 more source

Pan-TRK Immunohistochemistry: An Example-Based Practical Approach to Efficiently Identify Patients With NTRK Fusion Cancer

, 2020
Fondos FEDER Plan Estatal I+D+I 2008–2011 y 2013-2016 iLUNG ProgramContext.— Food and Drug Administration–approved TRK inhibitors with impressive overall response rates are now available for patients with multiple cancer types that harbor NTRK ...
Camacho, Carmen, Conde Gallego, Esther, Regojo, Rita María, Alonso, Marta, Hernández, Susana, Martínez, Rebeca, López-Ríos Moreno, Fernando, Sánchez, Elena   +7 more
core   +1 more source

Interlaboratory Comparison Study (Ring Test) of Next-Generation Sequencing–Based NTRK Fusion Detection in South Korea [PDF]

, 2022
PURPOSE: Tropomyosin receptor kinase (TRK) inhibitors are approved for the treatment of neurotrophic receptor tyrosine kinase (NTRK) fusion-positive tumors. The detection of NTRK fusion using a validated method is required before therapeutic application.
Seung Eun Lee, Lee, Mi-Sook, Jihun Kim, Jun Kang, Jeon, Yoon Kyung, Kang, Jun, Yoon Kyung Jeon, Choi, Yoon-La, Yoon-La Choi, Hyo Sup Shim, Lee, Seung Eun, Mi-Sook Lee, Shim, Hyo Sup, Kim, Jihun   +13 more
core   +2 more sources

Estimated overall survival in the unselected NTRK⁻cohort based on the tumor types observed in the NTRK⁺ cohort.

, 2022
Abbreviations: NTRK-, neurotrophic tropomyosin receptor kinase fusion negative; NTRK+, neurotrophic tropomyosin receptor kinase fusion positive. (TIF)
Solange Peters (318041), George D. Demetri (13215254), Laura Perez (3414401), Jessica Davies (3927101), Derrek P. Hibar (4502119), Olivier Humblet (2285017), Sophia L. Maund (11189433)   +6 more
core   +1 more source